{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:26:11Z","timestamp":1770647171859,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00345-019-02812-9","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T10:02:41Z","timestamp":1559296961000},"page":"293-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie\u2019s disease results in reduced procedural morbidity using a standardized hematoma classification rubric"],"prefix":"10.1007","volume":"38","author":[{"given":"Arash","family":"Amighi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram V.","family":"Eleswarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith V.","family":"Regets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Mendhiratta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-7071","authenticated-orcid":false,"given":"Jesse N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"issue":"1","key":"2812_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd (2013) Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190(1):199\u2013207. \nhttps:\/\/doi.org\/10.1016\/j.juro.2013.01.087","journal-title":"J Urol"},{"issue":"1","key":"2812_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, Kaufman GJ, Tursi JP, Ralph DJ (2015) Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med 12(1):248\u2013258. \nhttps:\/\/doi.org\/10.1111\/jsm.12731","journal-title":"J Sex Med"},{"issue":"4","key":"2812_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, Burnett AL (2015) Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 116(4):650\u2013656. \nhttps:\/\/doi.org\/10.1111\/bju.13096","journal-title":"BJU Int"},{"key":"2812_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","volume":"119","author":"K Wymer","year":"2018","unstructured":"Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L (2018) Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie\u2019s disease. Urology 119:109\u2013114. \nhttps:\/\/doi.org\/10.1016\/j.urology.2018.06.003","journal-title":"Urology"},{"key":"2812_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","volume":"104","author":"MJ Ziegelmann","year":"2017","unstructured":"Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW (2017) Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology 104:102\u2013109. \nhttps:\/\/doi.org\/10.1016\/j.urology.2017.01.054","journal-title":"Urology"},{"issue":"11","key":"2812_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","volume":"14","author":"DJ Ralph","year":"2017","unstructured":"Ralph DJ, Abdel Raheem A, Liu G (2017) Treatment of Peyronie\u2019s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med 14(11):1430\u20131437. \nhttps:\/\/doi.org\/10.1016\/j.jsxm.2017.08.015","journal-title":"J Sex Med"},{"issue":"4","key":"2812_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.sxmr.2017.07.005","volume":"5","author":"A Abdel Raheem","year":"2017","unstructured":"Abdel Raheem A, Johnson M, Abdel-Raheem T, Capece M, Ralph D (2017) Collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease\u2014a review of the literature and a new modified protocol. Sex Med Rev 5(4):529\u2013535. \nhttps:\/\/doi.org\/10.1016\/j.sxmr.2017.07.005","journal-title":"Sex Med Rev"},{"key":"2812_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","volume":"100","author":"J Anaissie","year":"2017","unstructured":"Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG (2017) Impact of number of cycles of collagenase Clostridium Histolyticum on outcomes in patients with Peyronie\u2019s disease. Urology 100:125\u2013130. \nhttps:\/\/doi.org\/10.1016\/j.urology.2016.09.050","journal-title":"Urology"},{"issue":"5","key":"2812_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13932","volume":"120","author":"A Abdel Raheem","year":"2017","unstructured":"Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, Ralph OG, Garaffa G, Christopher AN, Ralph DJ (2017) Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease using a new modified shortened protocol. BJU Int 120(5):717\u2013723. \nhttps:\/\/doi.org\/10.1111\/bju.13932","journal-title":"BJU Int"},{"issue":"4","key":"2812_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/andr.12497","volume":"6","author":"M Capece","year":"2018","unstructured":"Capece M, Cocci A, Russo G, Cito G, Giubilei G, Cacciamani G, Garaffa G, Falcone M, Timpano M, Tasso G, Sessa F, Campi R, Di Maida F, Cai T, Morelli G, Giammusso B, Verze P, Palmieri A, Ralph D, Mirone V, Mondaini N (2018) Collagenase Clostridium histolyticum for the treatment of Peyronie\u2019s disease: a prospective Italian multicentric study. Andrology 6(4):564\u2013567. \nhttps:\/\/doi.org\/10.1111\/andr.12497","journal-title":"Andrology"},{"issue":"10","key":"2812_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG (2017) Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med 14(10):1220\u20131225. \nhttps:\/\/doi.org\/10.1016\/j.jsxm.2017.08.008","journal-title":"J Sex Med"},{"issue":"5","key":"2812_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bju.13120","volume":"116","author":"CC Carson 3rd","year":"2015","unstructured":"Carson CC 3rd, Sadeghi-Nejad H, Tursi JP, Smith TM, Kaufman GJ, Gilbert K, Honig SC (2015) Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie\u2019s disease (PD). BJU Int 116(5):815\u2013822. \nhttps:\/\/doi.org\/10.1111\/bju.13120","journal-title":"BJU Int"},{"issue":"2","key":"2812_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.sxmr.2017.07.011","volume":"6","author":"JA Beilan","year":"2018","unstructured":"Beilan JA, Wallen JJ, Baumgarten AS, Morgan KN, Parker JL, Carrion RE (2018) Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture. Sex Med Rev 6(2):272\u2013278. \nhttps:\/\/doi.org\/10.1016\/j.sxmr.2017.07.011","journal-title":"Sex Med Rev"},{"key":"2812_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","volume":"94","author":"KK Yang","year":"2016","unstructured":"Yang KK, Bennett N (2016) Peyronie\u2019s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology 94:143\u2013147. \nhttps:\/\/doi.org\/10.1016\/j.urology.2016.04.049","journal-title":"Urology"},{"key":"2812_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-019-0126-y","author":"TA Masterson","year":"2019","unstructured":"Masterson TA, Galante A, Butaney M, Pastuszak A, Sadeghi-Nejad H, Ramasamy R (2019) Variation in collagenase Clostridium histolyticum practice patterns: a survey of ISSM members. Int J Impot Res. \nhttps:\/\/doi.org\/10.1038\/s41443-019-0126-y","journal-title":"Int J Impot Res"},{"issue":"2","key":"2812_CR16","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","volume":"5","author":"I Goldstein","year":"2017","unstructured":"Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, McMahon CG (2017) Changes in the effects of Peyronie\u2019s disease after treatment with collagenase Clostridium histolyticum: male patients and their female partners. Sex Med 5(2):e124\u2013e130. \nhttps:\/\/doi.org\/10.1016\/j.esxm.2017.02.001","journal-title":"Sex Med"},{"issue":"4","key":"2812_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ (2016) Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie\u2019s disease. J Sex Med 13(4):684\u2013689. \nhttps:\/\/doi.org\/10.1016\/j.jsxm.2016.02.105","journal-title":"J Sex Med"},{"key":"2812_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000000032","author":"WJG Hellstrom","year":"2019","unstructured":"Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A, Ziegelmann M, Trost L, Gelbard M (2019) Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol. \nhttps:\/\/doi.org\/10.1097\/ju.0000000000000032","journal-title":"J Urol"},{"key":"2812_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-019-0127-x","author":"T Masterson","year":"2019","unstructured":"Masterson T, Patel P, Ramasamy R (2019) Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie\u2019s disease. Int J Impot Res. \nhttps:\/\/doi.org\/10.1038\/s41443-019-0127-x","journal-title":"Int J Impot Res"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02812-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02812-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:25:10Z","timestamp":1590794710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02812-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2812"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02812-9","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Jesse Mills is on the speakers\u2019 bureau for Endo International pharmaceuticals. No other authors have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}